FDA and DEA call on ADHD drug manufacturers to up production amid ongoing shortages

The US FDA and Drug En­force­ment Ad­min­is­tra­tion sent a joint let­ter Tues­day to the pub­lic say­ing that they’re work­ing over­time try­ing to wran­gle short­ages of Adder­all and oth­er stim­u­lant med­ica­tions used to treat AD­HD.

While the FDA and DEA can­not force man­u­fac­tur­ers to in­crease their sup­plies, the two agen­cies said that last year, man­u­fac­tur­ers of am­phet­a­mines like Adder­all did not hit their quo­tas for how much they can legal­ly pro­duce.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters